Jody Agena, PharmD, MBA, director of pharmacy operations, Virginia Cancer Specialists, discusses the various responsibilities of the pharmacist within community oncology settings.
The pharmacists plays an important role when it comes to managing adverse effects, providing counseling, and bringing new protocols and initiatives to community oncology, says Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists.
This transcript was lightly edited for clarity; captions were auto-generated
Transcript
How can the pharmacist help manage side effects and support adherence to complex oncology regimens?
The clinical pharmacist in our practice plays an instrumental role in managing the side effects of the patients, safety, and clinical education, not only for the patients, but for the nursing staff as well as the providers. I think the pharmacist plays a key role in not only managing these side effects, but also counseling the patients and counseling on SOPs [standard operating procedures], protocols, and initiatives in the practice. I think the value that the pharmacist brings to a community practice in this community oncology setting is vital.
What strategies can pharmacists use to identify and prevent drug interactions or duplications in patients with multiple prescriptions?
This is an evolving field. I'm biased as a pharmacist; however, especially in the community oncology setting, it’s a newish type of multidisciplinary practice that is more and more embedded into the patient care model. What I mean by that is, I think a lot of the providers are starting to see the value that pharmacists bring, as far as an ancillary or supportive staff type of model. Providers don't have the time or bandwidth to look at drug interactions, to look complicated regimens, to look at sequencing, even to look at the appropriate antiemetics and supportive care and managing the clinical safety of these patients. More and more drugs, new medications are coming out on a daily basis, and it's impossible to keep up—especially when you're a community oncology provider, where you're seeing every single disease type under the sun. It's very difficult to keep up.
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More